Products

LegacyShield

UPGRADE YOUR SECURITY WITHOUT REPLACING YOUR LEGACY SYSTEMS

coderionlabs.com Security & Privacy / Application & Cloud Security

Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
$999/mo
Higher than 97% of peersNiche median $24.99/mo
Creators
Unlinked
No verified creators
Launched
2y ago
2024-08-16 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    Upgrade your security without replacing your legacy systems

    Aug 16, 2024 · 2y agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2024-05-09

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Basic Plan
Unknown
Pro Plan
$999/mo
Protects up to 9 types devices

Trial: None · 1 paid tier ($999) · Observed 2026-11-07 · Source page

Entry price $999/mo, Higher than 97% of peers; “Application & Cloud Security” median is $24.99/mo.View pricing benchmark

Website snapshots

Indexed 2024-08-16

Key pages

Desktop & mobile archive
coderionlabs.com/ Snapshot 2026-11-08

Questions & evidence

How much does LegacyShield cost?
Basic Plan: Unknown; Pro Plan: $999/mo. Observed 2026-11-07. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does LegacyShield get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is LegacyShield and what platforms does it support?
LegacyShield is catalogued under Application & Cloud Security: UPGRADE YOUR SECURITY WITHOUT REPLACING YOUR LEGACY SYSTEMS. Supported platforms: Web.

Related products in this category

Security & Privacy / Application & Cloud Security

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.